Related references
Note: Only part of the references are listed.Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
Ulrich Costabel et al.
ADVANCES IN THERAPY (2014)
Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts
Enrico Conte et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Talmadge E. King et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis
Fernando J. Martinez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Real world experiences: Pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis
Nazia Chaudhuri et al.
RESPIRATORY MEDICINE (2014)
Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
Dominique Valeyre et al.
RESPIROLOGY (2014)
Guidelines for the Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis
Antoni Xaubet et al.
ARCHIVOS DE BRONCONEUMOLOGIA (2013)
Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis
F. Bonella et al.
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT (2013)
A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis
Imre Noth et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis
Ganesh Raghu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature
Luba Nalysnyk et al.
EUROPEAN RESPIRATORY REVIEW (2012)
An Official ATS/ERSARS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Pirfenidone In Idiopathic Pulmonary Fibrosis
Natalie J. Carter
DRUGS (2011)
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Paul W. Noble et al.
LANCET (2011)
Pirfenidone in idiopathic pulmonary fibrosis
H. Taniguchi et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology
C. Vancheri et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults
C. M. Rubino et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2009)
Superoxide scavenging activity of pirfenidone-iron complex
Yoshihiro Mitani et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis
Hisashi Oku et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis
A Azuma et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis
S Nagai et al.
INTERNAL MEDICINE (2002)
Pirfenidone suppresses tumor necrosis factor-α, enhances interleukin-10 and protects mice from endotoxic shock
H Oku et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy
M Selman et al.
ANNALS OF INTERNAL MEDICINE (2001)
Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation
SN Iyer et al.
INFLAMMATION (2000)
Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals
HP Misra et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2000)
Share Paper
